Interpretation Variability of 18FDG-Positron Emission Tomography Studies in Dementia

Investigative Radiology

Volumn 31, Issue 6, 1996, Pages 316-322

  Hoffman, John M ^a,b   Hanson, Michael W ^a   Welsh, Kathleen A ^a   Earl, Nancy ^a   Paine, Susan ^a   Delong, David ^a   Coleman, R Edward ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18FDG positron emission tomography; Dementia; Variability; Visual interpretation

Indexed keywords

DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEMENTIA; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSERVER VARIATION; SCINTISCANNING; ALZHEIMER DISEASE; AMNESIA; BRAIN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; MAJOR CLINICAL STUDY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; TEMPORAL LOBE;

ADULT; AGED; DEMENTIA; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029664927     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199606000-00002     Document Type: Article

References (41)

1. Riege WH, Metter EJ. Cognitive and brain imaging measures of Alzheimer's disease. Neurobiol Aging 1988;9:69-86.
2. Katzman R, Alzheimer's disease. N Engl J Med 1986;314:964-973.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-944.
4. Morris, JC, McKeel DW, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol 1988;24:17-22.
5. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). I: Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
6. Khachaturian LS. Diagnoses of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
7. Farrer LA, Cupples LA, Blackburn S, et al. Interrater agreement for diagnosis of Alzheimer's disease: The Mirage study. Neurology 1994;44:652-656.
8. Lopez OL, Swilant AA, Becker JT, et al. Reliability of NINCDS-ADRDA clinical criteria for the diagnoses of Alzheimer's disease. Neurology 1990;40:1517-1522.
9. Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby M, Hughes J. Inter-rater reliability of Alzheimer's disease diagnosis. Neurology 1990;40:257-260.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987:97-163.
11. World Health Organization. Mental behavioral and developmental disorders, clinical description, and diagnostic guidelines. In: International statistical classification of diseases and related health problems. 10th revision. Geneva, Switzerland: World Health Organization, 1992.
12. Baldereschi M, Amato MP, Nencini P, et al. Cross-national interrater agreement on the clinical diagnostic criteria for dementia. Neurology 1994;44:239-242.
13. Fratiglioni L, Grut M, Forsell Y, Vitanen M, Winblad B. Clinical diagnosis of Alzheimer's disease and other dementias in a population survey agreement and causes of disagreement in applying diagnostic and statistical manual of mental disorders, revised third edition criteria. Arch Neurol 1992;49:927-932.
14. Davis PC, Gray L, Alhert M, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). III: Reliability of a standardized MRI evaluation of Alzheimer's disease. Neurology 1992;42:1676-1680.
15. Erkinjuntti T, Lee DH, Gao F, et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. Arch Neurol 1993;50:305-310.
16. Kido DK, Caine ED, LeMay M, Ekholm S, Booth H, Ponzer R. Temporal lobe atrophy in patients with Alzheimer's disease: A CT study. AJNR Am J Neuroradiol 1989;10:551-555.
17. Paulus W, Boncher C, Jellinger K. Interrater reliability in the neuropathologic diagnosis of Alzheimer's disease. Neurology 1992;42:329-332.
18. 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:711-714.
19. 18F] fluorodeoxyglulcose (FDG) and positron emission tomography in aging and dementia. Eur Neurol 1989;29(suppl 3):16-24.
20. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887.
21. Haxby JV, Grady CL, Durara R, Schlageter N, Berg G, Rapoport SI. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's type dementia. Arch Neurol 1986;43:882-885.
22. Rapaport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: A critical review. Cerebrovasc Brain Metab Rev 1991;3:297-335.
23. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 1987;44:258-262.
24. Bonte FJ, Tintner R, Weiner MF, Bigle BH, White CL. Brain blood flow in the dementias: SPECT with histopathologic correlation. Radiology 1993;186:361-365.
25. Powers WJ, Perlmutter JS, Videen TO, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 1992;42:765-770.
26. Herholz K, Perani D, Salmon E, et al. Comparability of FDG-PET studies in probable Alzheimer's disease. J Nucl Med 1993;34: 1460-1466.
27. Welsh K, Butters N, Hugles J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991;48:278-281.
28. Folstein MF, Holstein SE, McHugh PR. Mini mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
29. 18F-labeled 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1981;22:372-375.
30. Huang SC, Hoffman EJ, Phelps ME, Kuhl DE. Quantitation in positron emission tomography: Two effects of inaccurate attenuation connection. J Comput Assist Tomogr 1979;3:804-814.
31. Landis RJ, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
32. DiChiro G, Brooks RA. PET Quantitation: Blessing and curse. J Nucl Med 1988;29:1603-1604.
33. LeMay M, Stafford JL, Sandor T. Statistical assessment of perceptual CT scan ratings in patients with Alzheimer type dementia. J Comput Assist Tomogr 1986;10:802-809.
34. Sandor T, Albert M, Stafford J, Harpley S. Use of compterized CT analysis to discriminate between Alzheimer patients and normal control subjects. AJNR Am J Neuroradiol 1988;9:1181-1187.
35. Ettlin TM, Staehelin HB, Kischka U, et al. Computed tomography, electroencephalography, and clinical features in the differential diagnosis of senile dementia: A perspective clinical pathologic study. Arch Neurol 1989;46:1217-1220.
36. Burns A, Jacoby R, Philpot M, Levy R. Computerized tomography in Alzheimer's disease methods of scan analysis, comparison with normal controls, and clinical/radiological associations. Br J Psychiatry 1991;159:609-614.
37. Baxter BS, Sorsenson JA. Factors affecting the measurement size and CT number in computed tomography. Invest Radiol 1981;16:337-341.
38. Wippold FJ, Gado MH, Morris JC, Duchek JM, Grant EA. Senile dementia and healthy aging: A longitudinal CT study. Radiology 1991;179:215-219.
39. Rusinek H, deLeon MJ, George AE, et al. Alzheimer disease: Measuring loss of cerebral gray mater with MR imaging. Radiology 1991;178:1109-1114.
40. Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 1991;41:51-54.
41. Seab JP, Jagust WJ, Wong STS, et al. Quantitative NMR measurement of hippocampal atrophy in Alzheimer's disease. Magn Reson Med 1988;8:200-208.